LY 2525623

Drug Profile

LY 2525623

Alternative Names: Anti-IL-23 antibody - Eli Lilly; Anti-IL-23 MAb - Eli Lilly; LY2525623

Latest Information Update: 25 Nov 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Inflammation mediator inhibitors; Interleukin 23 inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Plaque psoriasis

Most Recent Events

  • 11 Nov 2010 Pharmacodynamics data from a preclinical study in Autoimmune arthritis presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2010)
  • 01 Mar 2010 Suspended - Phase-II for Plaque psoriasis in Canada (IV)
  • 01 Mar 2010 Suspended - Phase-II for Plaque psoriasis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top